Diligence memo · auto-generated · as of July 2, 2026
Alto Pharmacy Holdings, Inc.
Alto Pharmacy Holdings, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Alto Pharmacy Holdings, Inc. operates in Biotech / Pharma, based in SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Alto Pharmacy Holdings, Inc. has raised $170M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $132M on 2022-01-14.
Most recent recorded round closed around 2022-01-14.
Valuation (modeled)modeled
Provath models Alto Pharmacy Holdings, Inc. at approximately $3.1B (range $614M–$5.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.61× the median modeled value of Series D+ Biotech / Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 4.5 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 3.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 97% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Colossal Biosciences Inc., Vedanta Biosciences, Inc., Seismic Therapeutic, Inc., Vignette Bio, Inc., PharmaCann Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.